11,621 Shares in Harrow, Inc. (NASDAQ:HROW) Purchased by Freestone Grove Partners LP

Freestone Grove Partners LP bought a new position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,621 shares of the company's stock, valued at approximately $390,000.

A number of other institutional investors have also recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its stake in shares of Harrow by 443.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock valued at $10,717,000 after purchasing an additional 194,480 shares during the period. Barclays PLC lifted its stake in shares of Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company's stock worth $2,365,000 after buying an additional 39,506 shares in the last quarter. Brookstone Capital Management purchased a new stake in shares of Harrow during the fourth quarter valued at approximately $275,000. SG Americas Securities LLC grew its holdings in shares of Harrow by 158.5% during the fourth quarter. SG Americas Securities LLC now owns 30,689 shares of the company's stock valued at $1,030,000 after buying an additional 18,815 shares during the last quarter. Finally, Sonora Investment Management Group LLC bought a new stake in shares of Harrow during the fourth quarter valued at approximately $518,000. Institutional investors own 72.76% of the company's stock.

Harrow Trading Up 3.4 %

Shares of NASDAQ:HROW traded up $0.81 during trading hours on Friday, hitting $24.40. 1,281,092 shares of the company's stock traded hands, compared to its average volume of 510,015. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The business has a fifty day moving average price of $24.79 and a 200-day moving average price of $32.67. Harrow, Inc. has a 1 year low of $11.39 and a 1 year high of $59.23. The firm has a market capitalization of $895.11 million, a P/E ratio of -25.96 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The business had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Equities analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. B. Riley lowered their price target on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and set a $57.00 price target on shares of Harrow in a research report on Monday, March 31st.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.